The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00079601" target="_blank" >RIV/65269705:_____/24:00079601 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/24:00135939 RIV/00098892:_____/24:10158634 RIV/00843989:_____/24:E0110960 RIV/00064190:_____/24:10001210

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.arbres.2023.12.002" target="_blank" >10.1016/j.arbres.2023.12.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Popis výsledku v původním jazyce

&lt;bold&gt;Introduction: &lt;/bold&gt;Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). &lt;bold&gt;Methods: &lt;/bold&gt;The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - &quot;lack of efficacy&quot; (LE) and &quot;intolerance&quot; (INT). &lt;bold&gt;Results: &lt;/bold&gt;While 263 (43%) of 612 patients received no second AF (&quot;non-switched&quot;), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P&lt;0.001). &lt;bold&gt;Conclusion: &lt;/bold&gt;The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.

Název v anglickém jazyce

The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry

Popis výsledku anglicky

&lt;bold&gt;Introduction: &lt;/bold&gt;Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). &lt;bold&gt;Methods: &lt;/bold&gt;The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - &quot;lack of efficacy&quot; (LE) and &quot;intolerance&quot; (INT). &lt;bold&gt;Results: &lt;/bold&gt;While 263 (43%) of 612 patients received no second AF (&quot;non-switched&quot;), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P&lt;0.001). &lt;bold&gt;Conclusion: &lt;/bold&gt;The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Archivos de Bronconeumologia

ISSN

0300-2896

e-ISSN

1579-2129

Svazek periodika

60

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

ES - Španělské království

Počet stran výsledku

8

Strana od-do

80-87

Kód UT WoS článku

001170483700001

EID výsledku v databázi Scopus

2-s2.0-85181946229